Medical Device

Profound Medical (TSX-V:PRN) the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance imaging combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December …

Profound Medical (TSX-V:PRN) the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance imaging combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

“2017 was truly a transformative year for Profound,” said Arun Menawat, Profound’s CEO. “With the growing success of the pilot commercial launch of TULSA-PRO® in Europe, combined with the acquisition of Philips’ Sonalleve® business, Profound made the leap from a development-stage medical device company to a platform company focused on growth. Through the last financing, we now also have the financial resources required to continue to further drive clinical adoption of TULSA-PRO® in Europe, advance development of the technology toward successful commercialization in the United States, and execute our commercial plans for the Sonalleve® business.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20050.97-570.42
TSXV810.00-46.62
DOW33444.97-820.40
S&P 5004272.27-125.67
NASD13327.54-441.38
ASX7175.80-166.60

COMMODITIES

Commodities
Gold1832.52-1.68
Silver23.64-0.63
Copper4.41-0.11
Palladium2126.50+29.50
Platinum1012.50-17.50
Oil82.68-2.46
Heating Oil2.58-0.06
Natural Gas3.95-0.05

DOWNLOAD FREE REPORTS

×